Pharmaceutical Production
Articles & Whitepapers
-
Rare Disease Research: from Diagnostic Development to Small Molecule Drug Development
Rare diseases, also known as orphan diseases, affect a small percentage of the population, making them particularly challenging to diagnose and treat. However, thanks to advancements in medical research and technology, significant progress has been made in the field of rare disease research, from developing accurate diagnostic tools to making effective small-molecule drugs. One of the biggest ...
-
Enzyme Molecular Dynamics Simulation Service: Unveiling the Intricate Dance of Life's Catalysts
As professional biologists, we are enthralled by the intricate dance of life's catalysts - enzymes. These remarkable protein molecules are the unsung heroes of the biological world, orchestrating the ...
News
-
ARAI-2PAM Barda Procurement Award
Broomfield, Colorado, 10/3/2022. Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response ...
FDA Emerging Technology Program
Aktiv Pharma Group Receives Grant Funding to Develop Tranexamic Acid Autoinjector
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
Equipment & Solutions
-
Showcase
Sanitary Process Connections
Provides and meets the necessary stringent sanitary and cleanliness requirements for the food and beverage, pharmaceutical and biotech industries.
Upcoming Events
-
Showcase
The 7th Global MASLD Congress
MASH/MASLD incidence rates are continuing to rise globally year after year as the disease continues to be a global health concern. Although no pharmaceutical drugs have yet received regulatory approval, there are a number of therapeutics in late phase clinical trials; case studies of which will be discussed at the congress as well as pre-clinical developments. Potential alternatives for MASH ...